GlassScriptPhysician profile
Deniene D King
NPI 1093107948
$14,180.45
in general payments reported to CMS, 2019-2025
18 companies · $5,007 in 2025
The $5,007 reported for 2025 was more than what 98% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,397 · 2022: $1,402 · 2023: $2,243 · 2024: $4,132 · 2025: $5,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $740 · Education: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,221.89 |
| Consulting Fee | $740.00 |
| Education | $419.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,368.36 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $2,222.85 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $2,080.41 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,776.07 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,259.71 | 2021-2025 | |
| Lundbeck LLC | $1,073.99 | 2021-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $894.66 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $583.29 | 2023-2025 | Lybalvi, Aristada, Aristada Initio |
| Axsome Therapeutics, INC. | $391.33 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $342.39 | 2023-2024 | Adlarity, Azstarys, Azstarys |
| Sunovion Pharmaceuticals INC. | $274.02 | 2021-2022 | |
| Braeburn INC. | $233.67 | 2025 | Brixadi |
| Supernus Pharmaceuticals, INC. | $194.54 | 2024-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $142.54 | 2021-2025 | Spravato |
| Biohaven Pharmaceuticals, INC. | $123.08 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $95.85 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.28 | 2023-2025 | Trintellix |
| Owp Pharmaceuticals, INC. | $29.41 | 2023-2024 | Subvenite, Lamotrigine |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deniene King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.